Combining Cisplatin and Temozolomide for Pediatric Cancer Treatment
Author Information
Author(s): Geoerger B, Vassal G, Doz F, O'Quigley J, Wartelle M, Watson A J, Raquin M-A, Frappaz D, Chastagner P, Gentet J-C, Rubie H, Couanet D, Geoffray A, Djafari L, Margison G P, Pein F
Primary Institution: Institut Gustave Roussy, Villejuif, France
Hypothesis
Cisplatin may have additive activity with temozolomide due to ablation of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (MGMT).
Conclusion
The combination of cisplatin and temozolomide is well tolerated in children and adolescents, generating no toxicity greater than that of the single agents.
Supporting Evidence
- 39 patients with refractory or recurrent solid tumors were treated.
- Partial responses were observed in several patients with malignant gliomas and neuroblastomas.
- Low MGMT activity correlated with increased severity of thrombocytopenia.
Takeaway
Doctors tested a new medicine combination to help kids with tough cancers, and it worked without making them sicker than usual.
Methodology
This phase I/II study used the Continual Reassessment Method to determine safe doses and evaluate toxicity and antitumor activity in pediatric patients.
Potential Biases
Potential bias due to the study design and patient selection criteria.
Limitations
The study included a small sample size and was limited to specific patient cohorts.
Participant Demographics
Median age was approximately 13 years; included 25 males and 14 females.
Statistical Information
P-Value
0.0004
Statistical Significance
p=0.0004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website